Market brief
UnitedHealth lifts outlook; Visa wins China nod – Market Brief, Oct 13, 2026
Published Oct 13, 2026
UnitedHealth reported Q3 results and raised its outlook, Visa won Chinese approval for bank card clearing, and Emerson filed quarterly results.
Takeaway: Health insurers led the day's corporate news: UnitedHealth filed third-quarter results and said its medical-cost ratio came in at 88.4%, while Humana made a separate disclosure to investors. Elsewhere, Visa received Chinese regulatory approval for a bank card business after decades of trying, and Emerson Electric filed its quarterly results with the SEC. A Federal Reserve policymaker also argued publicly for tighter policy to keep inflation expectations in check.
UnitedHealth reports Q3 and raises its outlook again
UnitedHealth Group filed an 8-K with its third-quarter results. Coverage said the insurer's medical-cost ratio — the share of premium money paid out as medical claims — was 88.4% in the quarter, and that it raised its outlook again as it works to contain spending on care.
Why it matters. The medical-cost ratio is the main lever in a health insurer's profit: the lower it is, the more premium income is left after paying claims. A raised outlook may suggest management feels more confident about claim costs for the rest of the year, though the filing itself is the only confirmed detail here. The site's last published figures for UnitedHealth were Q2 2026 revenue of $112.0B (+0.4%) and EPS of $6.04 (+61.5%).
On this site: UNH Q2 2026 analysis
Sources: SEC EDGAR (8-K) · MarketWatch
Humana files a Regulation FD disclosure
Humana filed an 8-K under Item 7.01, the section used for Regulation FD disclosures — information a company shares publicly so that no investor gets it first. No details beyond the filing itself were given in the source.
Why it matters. Such filings often accompany investor presentations or guidance updates, and they arrive on the same day as a large peer's quarterly results. The site's last published figures for Humana were Q2 2026 revenue of $40.9B (+26.2%) and EPS of $5.73 (+27.1%).
On this site: HUM Q2 2026 analysis
Sources: SEC EDGAR (8-K)
Visa cleared by Beijing for bank card business
CNBC reported that Chinese authorities approved Visa to operate a bank card business, after roughly 40 years of the company working with China. The report noted the approval comes ahead of a planned third meeting this year between the U.S. and Chinese presidents next month.
Why it matters. Approval could open a domestic payments market that Visa has long been outside of, though the report gives no figures on scale or timing. The site's last published figures for Visa were Q3 2026 revenue of $11.6B (+14.4%) and EPS of $2.97 (+10.4%).
On this site: V Q3 2026 analysis
Sources: CNBC
Fed's Hammack argues for higher rates on inflation
Cleveland Fed President Beth Hammack said tighter monetary policy — higher interest rates — could be needed to bring inflation down and stop an "inflationary mindset" from setting in, according to CNBC. Separately, CNBC reported that prediction-market traders see little chance core inflation, which strips out food and energy, drops to 2.2% this year.
Why it matters. These are views, not policy decisions. Still, debate inside the Fed about whether rates are high enough may shape how borrowing costs for companies and households move. Traders appearing to expect inflation to stay above 2.2% suggests the issue is not seen as resolved.
Emerson Electric files quarterly results
Emerson Electric submitted an 8-K under Item 2.02, the item used to report results of operations and financial condition. The source item gives no figures from the release.
Why it matters. Emerson sells automation equipment to industrial customers, so its numbers are often read as a gauge of factory and infrastructure spending. The site's last published figures were Q3 2026 revenue of $4.9B (+7.0%) and EPS of $1.28 (+23.1%).
On this site: EMR Q3 2026 analysis
Sources: SEC EDGAR (8-K)
Kenvue signs a material agreement; Kimberly-Clark files other events
Kenvue filed an 8-K reporting entry into a material definitive agreement, with exhibits attached. Kimberly-Clark filed an 8-K under Item 8.01, the catch-all "other events" category, also with exhibits. Neither source item describes the contents.
Why it matters. A "material definitive agreement" is a contract important enough that investors must be told, but the filing summary alone does not say what it covers. Readers would need the exhibits themselves for detail. The site's last published figures were Kenvue Q2 2026 revenue of $4.0B (+3.0%) and Kimberly-Clark Q2 2026 revenue of $4.2B (+0.6%).
On this site: KVUE Q2 2026 analysis · KMB Q2 2026 analysis
Sources: SEC EDGAR (8-K) · SEC EDGAR (8-K) (2)
What to watch next
- ASML reports third-quarter results before the market opens in Amsterdam on Wednesday, per MarketWatch
- The U.S. and Chinese presidents are due to meet for a third time this year next month, per CNBC
- Options traders are positioned for larger stock-market swings starting later this month, per MarketWatch
This brief is compiled from public feeds (official releases, SEC filings and financial press headlines). It paraphrases and links to each source and may miss context in the full articles, so check the linked sources before relying on it. For information only; not investment advice.
Related analyses
- UnitedHealth Group (UNH) · Q3 2026Revenue $112.7B (-0.4%) · EPS $4.56 (+76.1%)
UnitedHealth's Q3 2026 operating earnings rose 52% to $6.6B on 0.4% lower revenue as the medical care ratio fell to 88.4% from 89.9% (helped by $610M of reserve releases), and full-year adjusted EPS guidance was raised to at least $20.50.
- Kenvue (KVUE) · Q2 2026Revenue $4.0B (+3.0%) · EPS $0.24 (+9.1%)
Kenvue grew Q2 2026 sales 3.0% (organic +1.6%), but inflation, tariffs and higher marketing spend held operating income to +1.0%; EPS rose to $0.24 mainly on a lower tax rate, and a July appeals ruling revived federal Tylenol lawsuits ahead of the Kimberly-Clark deal expected to close in Q4.
- Humana (HUM) · Q2 2026Revenue $40.9B (+26.2%) · EPS $5.73 (+27.1%)
Humana's Q2 2026 revenue rose 26.2% to $40.9B and diluted EPS rose 27.1% to $5.73 on 23% Medicare Advantage membership growth, but its benefit ratio rose to 91.1% from 89.7% on a Star Ratings revenue cut and costlier new members.
- Emerson Electric (EMR) · Q3 2026Revenue $4.9B (+7.0%) · EPS $1.28 (+23.1%)
Emerson's fiscal Q3 2026 sales rose 7% (6% underlying) to $4.87B and diluted EPS rose to $1.28 from $1.04, helped by an $82M tariff refund; adjusted EPS of $1.71 (+13%) beat guidance and full-year guidance was raised.
For information only; not investment advice.